Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M71.7Revenue $M1.3Net Margin (%)-368.0Z-Score-6.5
Enterprise Value $M20.9EPS $-2.1Operating Margin %-354.5F-Score3
P/E(ttm))0Cash Flow Per Share $0.8Pre-tax Margin (%)-368.0Higher ROA y-yY
Price/Book1.410-y EBITDA Growth Rate %0Quick Ratio2.6Cash flow > EarningsN
Price/Sales3.45-y EBITDA Growth Rate %0Current Ratio2.6Lower Leverage y-yY
Price/Cash Flow7.1y-y EBITDA Growth Rate %0ROA % (ttm)-44.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-87.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M52.3ROI % (ttm)-74.6Gross Margin Increase y-yN

Gurus Latest Trades with AVEO

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AVEOGeorge Soros 2014-06-30 Buy $1.02 - $1.72
($1.29)
$ 1.23-5%New holding, 49076 sh.49,076
AVEOSeth Klarman 2013-06-30 Reduce-0.26%$2.34 - $8.27
($4.27)
$ 1.23-71%Reduce -21.9%3,829,350
AVEOGeorge Soros 2011-12-31 Sold Out -0.0031%$14.53 - $17.35
($8.42)
$ 1.23-85%Sold Out0
AVEOSeth Klarman 2011-09-30 Add0.29%$15.12 - $20.77
($17.66)
$ 1.23-93%Add 12.79%5,000,000
AVEOGeorge Soros 2011-09-30 Reduce-0.04%$15.12 - $20.77
($17.66)
$ 1.23-93%Reduce -92.8%11,600
AVEOSeth Klarman 2011-06-30 Add0.78%$13.06 - $20.66
($16.79)
$ 1.23-93%Add 25.76%4,433,010
AVEOGeorge Soros 2011-06-30 Buy 0.05%$13.06 - $20.66
($16.79)
$ 1.23-93%New holding, 161000 sh.161,000
AVEOSeth Klarman 2011-03-31 Add1.15%$13.15 - $15.02
($14.21)
$ 1.23-91%Add 76.25%3,525,000
AVEOSeth Klarman 2010-12-31 Buy 1.68%$13.84 - $17.41
($15.14)
$ 1.23-92%New holding, 2000000 sh.2,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AVEO is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AVEO George Soros 2014-06-3049,0760.090New Buy
AVEO Seth Klarman 2014-06-303,829,3507.330.11
Premium Most recent portfolio changes are included for Premium Members only!


AVEO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Vittiglio JosephSVP, General Counsel 2014-01-30Sell5,430$1.64-30.49view
Gyuris JenoSVP, Chief Scientific Officer 2014-01-30Sell5,430$1.64-30.49view
Slichenmyer WilliamChief Medical Officer 2014-01-30Sell5,430$1.64-30.49view
BAILEY MICHAEL PChief Business Officer 2014-01-30Sell5,430$1.64-30.49view
Johnston David BrannonCFO 2013-03-14Sell1,061$7.34-84.47view
TERMEER HENRI ADirector 2013-03-07Buy55,499$6.73-83.06view
YOUNG ROBERT CDirector 2013-02-19Buy990$6.6-82.73view
KUCHERLAPATI RAJU SDirector 2012-12-13Buy15,000$6.74-83.09view
HA NGOC TUANCEO 2012-12-13Buy75,000$6.65-82.86view
TERMEER HENRI ADirector 2012-12-13Buy44,501$6.6-82.73view

Press Releases about AVEO :

    Quarterly/Annual Reports about AVEO:

    News about AVEO:

    Articles On GuruFocus.com
    Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
    Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
    comment on AVEO Mar 15 2013 
    comment on AVEO Mar 15 2013 
    Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
    Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
    Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
    AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
    Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
    Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

    More From Other Websites
    Clinical Data on AVEO Oncology’s Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014... Sep 17 2014
    AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? Aug 21 2014
    Biotechnology Stocks to Keep an Eye On Aug 20 2014
    AVEO PHARMACEUTICALS INC Financials Aug 19 2014
    AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss Aug 13 2014
    AVEO Oncology Reports Second Quarter 2014 Financial Results and Updates Progress on Strategic Plan Aug 11 2014
    AVEO PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 11 2014
    Framing Up Capital Efficiency In Early Stage Biotech Jul 17 2014
    AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 6.4% Jul 01 2014
    Can the Uptrend Continue for AVEO Pharmaceuticals (AVEO)? Jun 26 2014
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 23 2014
    AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 11.4% Jun 18 2014
    $5 Or Less: 3 Small, Speculative Biotechs On The Move Jun 17 2014
    Five Biotech Stocks With Big Potential And Billionaire Believers Jun 16 2014
    AVEO PHARMACEUTICALS INC Files SEC form 8-K/A, Costs Associated with Exit or Disposal Activities Jun 13 2014
    AVEO Pharmaceuticals, Inc. (AVEO) in Focus: Stock Rises 7.8% Jun 10 2014
    AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical... May 31 2014
    AVEO Oncology to Present at the Jefferies Global Healthcare Conference May 28 2014
    PTC Therapeutics Up on Positive CHMP Opinion May 27 2014
    Sarepta to Acquire Manufacturing Facility May 23 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK